Skip to content

Biohaven BHVN Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.48M+60.0%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$814K-199%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$382K+92.4%
Roivant Sciences logo
Roivant SciencesROIV
$1.85M-15.3%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$1.92M+102%

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.23B-48.1%
Enterprise value$2.23B-46.3%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's change in other assets?
Biohaven (BHVN) reported change in other assets of -$12.56M in Q1 2026.
How has Biohaven's change in other assets changed year-over-year?
Biohaven's change in other assets decreased by 273.6% year-over-year, from $7.24M to -$12.56M.
What is the long-term trend for Biohaven's change in other assets?
Over 3 years (2021 to 2025), Biohaven's change in other assets has grown at a 218.8% compound annual growth rate (CAGR), from $109K to -$3.53M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.